NeuronesXPAR:NRO -0.28%96 EBITDA Margin % is 13.42% as of Dec. 2025, which is 1% above its 10-year median of 13.32. GuruFocus rates XPAR:NRO with a GF Score™ of 96/100 and a GF Value™ of €50.23 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 2,818 Software companies, Neurones ranks better than 62.07% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neurones's EBITDA for the
six
months ended in Dec. 2025 was €58.1 Mil. Neurones's Revenue for the
six
months ended in Dec. 2025 was €432.9 Mil. Therefore, Neurones's EBITDA margin for the quarter that ended in Dec. 2025 was 13.42%.
Neurones (XPAR:NRO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neurones EBITDA Margin % Related Terms
Neurones EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neurones's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:NRO vs IBM, ACN, FISV: EBITDA Margin % Comparison
For the Information Technology Services subindustry, Neurones's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurones EBITDA Margin % vs Software Industry
For the Software industry and Technology sector, Neurones's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neurones's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurones (XPAR:NRO) has a EBITDA Margin % of 13.42% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neurones and its competitors. This is near median its historical median of 13.32. Over the past decade, Neurones' EBITDA Margin % has ranged from 11.43 to 13.82. According to the industry distribution chart, Neurones ranks #1069 out of 2818 companies in the Software industry, placing it in the top 37.9%.
Is Neurones' EBITDA Margin % too high?
Neurones' current EBITDA Margin % of 13.42% is near median its 10-year median of 13.32. Over the past 10 years, this metric has ranged from a low of 11.43 to a high of 13.82. The Software industry median EBITDA Margin % is 8.07. Neurones' value of 13.42% is 66.3% above this industry median. Based on the distribution chart, Neurones ranks #1069 out of 2818 companies in the Software industry, which is above the industry midpoint. Overall, Neurones has a GF Score™ of 96/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurones' EBITDA Margin % compare to IBM and ACN?
According to the Software industry distribution chart, Neurones ranks #1069 out of 2818 companies for EBITDA Margin %. This puts Neurones in the upper half of its industry. The industry median EBITDA Margin % is 8.07. Neurones' value of 13.42% is 66.3% above this benchmark. Historically, Neurones' own EBITDA Margin % has ranged from 11.43 to 13.82 over the past decade. While the company's 10-year median is 13.32 vs. the industry median of 8.07, Neurones has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Software company?
The median EBITDA Margin % among Software companies is 8.07, based on 2,818 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurones's current EBITDA Margin % of 13.42% is 66.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neurones and its competitors. For the Software industry, the median EBITDA Margin % is 8.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurones's current EBITDA Margin % is 13.42%, which is near median its own 10-year median of 13.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurones stock overvalued right now?
Based on GuruFocus' analysis, Neurones (XPAR:NRO) is currently considered Significantly Undervalued. The stock's GF Value™ is €50.23, compared to a current price of €35.10 — trading 30.1% below its estimated fair value. The current EBITDA Margin % is 13.42%, which is near median its 10-year median of 13.32 and 66.3% above the Software industry median of 8.07. Neurones' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neurones (XPAR:NRO), the current EBITDA Margin % is 13.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurones (XPAR:NRO) Overvalued in 2026?
Based on GuruFocus' analysis, Neurones stock appears to be undervalued.
The current stock price of €35.10 is trading 30.1% below its estimated GF Value™ of €50.23.
GuruFocus considers Neurones to be Significantly Undervalued.
Key valuation signals for XPAR:NRO:
EBITDA Margin %: 13.42% (near median its 10-year median of 13.32)
GF Value™: €50.23 vs. price of €35.10 (30.1% below fair value)
Industry Position: 66.3% above the Software median (#1069 of 2818)
No single metric tells the full story. See the XPAR:NRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurones is active in Consulting and Digital Services, with activities including Digital Transformation, Overall Offer, Infrastructure Hub, Applications Hub, Consulting Division, Managed Services, and Service Centers. It also conducts IT development, pre-sales activities, management of fixed-price projects, technical assistance, infrastructure operations, and cybersecurity, and provides an internal platform for multi-LLM assistants, including Microsoft Copilot, ChatGPT, Gemini, Claude, and Mistral. Its segments are Infrastructure Services, Application Services, and Consulting. Infrastructure Services generates the majority of revenue and includes Cloud, Infrastructure Management, DevOps, Cybersecurity, User Support, IT Service Management, Information System Governance, and Automation.
96GF Score
Get the complete analysis for XPAR:NRO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:NRO has been successfully added to your 
